Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 236.00
Bid: 232.00
Ask: 240.00
Change: 0.00 (0.00%)
Spread: 8.00 (3.448%)
Open: 233.00
High: 236.00
Low: 233.00
Prev. Close: 236.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update & Notice of Results

14 Jan 2015 07:00

RNS Number : 0699C
Animalcare Group PLC
14 January 2015
 



 

Animalcare Group plc

("Animalcare" or the "Group")

Trading Update & Notice of Results

 

Animalcare, a leading supplier of veterinary medicines, provides the following trading update for the six months ended 31st December 2014, in advance of releasing its interim results on Tuesday 24th February 2015.

 

Trading Update

 

The Board is pleased to report a solid trading performance for the period ended 31st December 2014. Revenues across the Group were up by approximately 7.2% to £6.93m (2013: £6.46m).

 

Revenue from sales of Licensed Veterinary Medicines was up 10.6% to £4.40m (2013: £3.98m). This increase includes planned organic growth and a non-recurring benefit from sales of Buprecare as a result of supply problems of a competitor product balanced by lower than expected sales of some older, lower margin pharmaceuticals.

 

Sales in the Companion Animal Identification group continued to perform well, increasing by 5.0% to £1.26m (2013: £1.20m) versus prior period. Microchip revenues were up in the period and other products and services in this group also performed well following further marketing investment in this area.

 

Revenues from the Animal Welfare group fell by 1.2% to £1.27m (2013: £1.29m) but, as observed in the previous financial year, with a moderate increase in gross profitability following the rationalisation of the less profitable products.

 

Operating cash flows have benefited from the planned reduction in stock levels, which will remain a focus area during the second half of the financial year. This, together with lower than planned investment in our product pipeline in the first half, have contributed to a higher than expected cash position of approximately £5.00m (30th June 2014: £3.81m, 31st December 2013: £3.75m).

 

Summary and Outlook

 

During the period Animalcare started the distribution of Pet Remedy in the UK and Ireland. Pet Remedy is a natural de-stressing and calming product for use with several companion animal species, crucially with the support of clinical studies.

 

The sales and marketing teams are planning the UK launch of three pharmaceutical products on behalf of a European partner in the second half and these are expected to make a small contribution to revenue in the current financial year with greater impact in the next year.

 

The product development pipeline activities are progressing well with expenditure weighted to the second half.

 

Compulsory microchipping for dogs in Wales has been delayed from March 2015 to a date still to be confirmed. Preparations are well underway for the Animalcare pet and owner database to be ready on the DEFRA timetable. Engagement by dog owners in preparation for the deadline in England in April 2016 has been slow but as this gathers momentum Animalcare is well placed to benefit.

 

Following the solid trading performance in the first half, particularly across the Licensed Veterinary Medicines and Companion Animal Identification product groups, the Board remains confident about the prospects and outcome for the full year.

 

 

For further information, please contact:

 

Animalcare Group plc

Tel: 01904 487 687

Iain Menneer, Chief Executive Officer

Chris Brewster, Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley/Peter Steel

Tel: 020 7886 2500

Walbrook PR Ltd

Tel: 020 7933 8780 or animalcare@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

Notes to editors

 

Animalcare is a leading veterinary sales and marketing company based in York with 57 employees including a field sales force of 14 representatives selling to all veterinary practices around the United Kingdom.

 

Animalcare has developed a range ofgeneric veterinary medicines and animal identification products primarily to companion animal veterinary markets.  

 

Animalcare operates in three product areas:

 

· Licensed Veterinary Medicines- a range of branded veterinary licensed pharmaceuticals sold to veterinary professionals in the UK and selected markets in Northern Europe. The range can be divided into four main categories; antibacterials, anaesthetics & analgesics, Aqupharm intravenous fluids and vitamins & speciality pharmaceuticals.

 

· Companion Animal Identification - Identichip is the pioneering microchip identification system in the UK. Animalcare also owns and operates the Anibase database; together the market leader in electronic identification for pets in the UK.

 

· Animal Welfare Products - a range used by veterinary professionals in the diagnosis and care of their patients, for example intravenous infusion accessories, ophthalmic instruments, hygiene solutions and bandages and dressings.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFVRLFIVLIE
Date   Source Headline
12th Jul 202111:04 amRNSNotification of Major Holding
12th Jul 20217:00 amRNSExercise of options
9th Jul 20214:59 pmRNSNotification of Major Holding
9th Jul 20213:20 pmRNSNotification of Major Holding
8th Jul 20215:45 pmRNSResult of Secondary Placing
8th Jul 20214:41 pmRNSSecond Price Monitoring Extn
8th Jul 20214:35 pmRNSPrice Monitoring Extension
8th Jul 20212:06 pmRNSSecond Price Monitoring Extn
8th Jul 20212:00 pmRNSPrice Monitoring Extension
8th Jul 20211:00 pmRNSProposed Secondary Placing
1st Jul 20217:00 amRNSTotal Voting Rights
21st Jun 20217:00 amRNSExercise of options
17th Jun 202110:17 amRNSDirector/PDMR Notification
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20215:03 pmRNSResult of 2021 AGM
17th May 20217:00 amRNSAnnual Report 2020 and Notice of AGM
22nd Apr 20217:00 amRNSDaxocox approved by EU and UK authorities
30th Mar 20217:00 amRNSFull Year Results 2020
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results
16th Jul 201911:37 amRNSNotification of major holdings
25th Jun 20191:40 pmRNSResult of AGM
19th Jun 20193:52 pmRNSBoard change
10th Jun 20192:55 pmRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSAnnual Report and Notice of Annual General Meeting
8th May 201910:35 amRNSDividend Declaration
30th Apr 20197:00 amRNS2018 Full Year Results
21st Jan 20197:00 amRNSTrading Update and Notice of Results
30th Oct 20187:50 amRNSAdditional Listing
1st Oct 201812:45 pmRNSAdditional Listing
25th Sep 20185:36 pmRNSDividend Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.